Axsome Therapeutics Inc (AXSM): Next-Year EPS Estimate 274.15%
As of 2026-08-26, Axsome Therapeutics Inc (AXSM) has a next-year EPS growth estimate of 274.15%. Featured in our EPS revision report on 2026-05-04.
On 2026-08-24, analyst consensus for AXSM's next-year EPS growth shifted from 276.98% to 274.15% — a negative change of 2.83 percentage points. The revised estimate has been sustained across 3 subsequent trading sessions. Current-year growth is projected at 27.32%.
What's Driving This
The primary structural driver is the upward revision in next-year EPS estimates, with analysts raising growth expectations to 280.13% despite a slight cut from 298.87%. This revision is plausibly supported by Axsome's strong sales growth in Q2 2026, which offset an earnings miss and was highlighted in recent headlines. Momentum appears to extend beyond the initial revision, as the stock continues to gain alongside ongoing clinical developments such as the FOCUS-2 Phase 3 trial for solriamfetol in ADHD.
Generated 2026-08-11 from news as of 2026-08-11
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 274.15%
- EPS growth this year
- 27.32%
- EPS next quarter (est)
- -$0.49
- Last price
- $206.17
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-26 | 274.15% | 27.32% | -$0.49 | $206.17 |
| 2026-08-25 | 274.15% | 27.32% | -$0.49 | $205.48 |
| 2026-08-24 | 274.15% | 27.32% | -$0.49 | $205.40 |
| 2026-08-23 | 276.98% | 27.59% | -$0.49 | $207.77 |
| 2026-08-21 | 276.98% | 27.59% | -$0.49 | $207.77 |
| 2026-08-20 | 276.98% | 27.59% | -$0.49 | $208.03 |
| 2026-08-19 | 276.98% | 27.59% | -$0.49 | $218.20 |
| 2026-08-18 | 276.98% | 27.59% | -$0.49 | $215.69 |
| 2026-08-17 | 276.98% | 27.59% | -$0.49 | $216.27 |
| 2026-08-16 | 276.98% | 27.59% | -$0.49 | $213.67 |
| 2026-08-14 | 276.98% | 27.59% | -$0.49 | $213.67 |
| 2026-08-13 | 280.85% | 28.70% | -$0.47 | $213.68 |
| 2026-08-12 | 280.85% | 28.70% | -$0.47 | $214.66 |
| 2026-08-11 | 280.13% | 28.97% | -$0.47 | $215.77 |
| 2026-08-10 | 298.87% | 29.14% | -$0.44 | $220.89 |
| 2026-08-09 | 336.82% | 37.58% | -$0.89 | $212.74 |
| 2026-08-07 | 336.82% | 37.58% | -$0.89 | $212.74 |
| 2026-08-06 | 336.82% | 37.58% | -$0.89 | $210.13 |
| 2026-08-05 | 336.82% | 37.58% | -$0.89 | $212.85 |
| 2026-08-04 | 336.82% | 37.58% | -$0.89 | $212.17 |
| 2026-08-03 | 336.82% | 37.58% | -$0.89 | $211.04 |
| 2026-08-02 | 336.82% | 37.58% | -$0.89 | $217.99 |
| 2026-07-31 | 336.82% | 37.58% | -$0.89 | $217.99 |
| 2026-07-30 | 328.50% | 38.01% | -$0.89 | $234.64 |
| 2026-07-29 | 328.63% | 37.49% | -$0.89 | $227.42 |
| 2026-07-28 | 328.63% | 37.49% | -$0.89 | $234.20 |
| 2026-07-27 | 327.46% | 37.29% | -$0.89 | $238.37 |
| 2026-07-26 | 327.46% | 37.29% | -$0.89 | $241.00 |
| 2026-07-24 | 327.46% | 37.29% | -$0.89 | $241.00 |
| 2026-07-23 | 327.46% | 37.29% | -$0.89 | $241.53 |
Reports Featuring AXSM
Recent News
- Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 missInvestorsHub
- Axsome: Q2 Earnings SnapshotAssociated Press
- Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Shopify downgraded, Five Below upgraded: Wall Street's top analyst callsThe Fly
- Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)GlobeNewswire
- TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay SchemeStocktwits
- TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay SchemeStocktwits
- Axsome Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby
- Axsome: Q1 Earnings SnapshotAssociated Press
- Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
Screen Performance
Aggregate stats across all 2015 tickers our top-EPS-revision screen has flagged over the past 147 days.
- Median return since detection
- +3.0%
- % of tickers in the green
- 56%
- Median return on winners
- +20.0%
- Large revisions captured
- 1609
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Axsome Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-08-26, Axsome Therapeutics Inc (AXSM) has a next-year EPS growth estimate of 274.15%, based on analyst consensus.
When was the latest EPS estimate revision for AXSM?▾
The most recent revision occurred on 2026-08-24, when analysts adjusted the next-year EPS growth estimate from 276.98% to 274.15%.
What sector and industry does Axsome Therapeutics Inc belong to?▾
Axsome Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. AXSM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Axsome Therapeutics Inc (AXSM) appears here because it was detected by our daily top-EPS-revision-performer screen.